• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Nuvasive Attrax Putty wins FDA expanded clearance for use in thoracolumbar interbody procedures

Nuvasive Attrax Putty wins FDA expanded clearance for use in thoracolumbar interbody procedures

January 5, 2022 By Danielle Kirsh

NuvasiveNuvasive today announced that its Attrax Putty received FDA 510(k) clearance for expanded indications in thoracolumbar interbody spine surgery.

Attrax Putty is a synthetic, bioactive and osteoconductive bone void filler that drives bone fusion. San Diego–based Nuvasive designed it with a surface microarchitecture that has an optimized environment for bone formation without added cells or growth factors.

A level I randomized controlled trial supports the bone grafting device as a bone graft substitute in posterolateral spinal fusions. In addition, recent studies demonstrated that Attrax Putty performs comparably to autograft bone in thoracolumbar interbody fusions, according to Nuvasive.

“The expanded indications of Attrax Putty with thoracolumbar implants support the clinical efficacy of Attrax Putty and highlight the comparative clinical advantage over competitive biologic offerings in the market,” chief technology officer Ryan Donahoe said in a news release. “This first and only 510(k) clearance of its kind demonstrates NuVasive’s commitment to advancing the standard of spine care—while delivering enhanced economic value to our customers.”

The expanded indication allows the company to use Attrax Putty with its procedurally integrated thoracolumbar interbody portfolio, including the Advanced Materials Science technologies of Modulus porous titanium and Cohere porous PEEK.

“I’m excited to see the FDA recognizing that the clinical results support the safe and effective use of these advanced implant combinations,” Robert Eastlack, an orthopedic spine surgeon at Scripps Health in San Diego, said. “In my practice and clinical research, patients treated with optimized porous titanium cages like Modulus XLIF in combination with Attrax Putty have shown notable radiographic and clinical success. This implant combination for spinal fusion has driven cost-savings at my institution while continuing to provide clinical value for my patients.”

Filed Under: 510(k), Featured, Food & Drug Administration (FDA), News Well, Orthopedics, Regulatory/Compliance, Spine Tagged With: Nuvasive

More recent news

  • Aurora Spine begins first procedures with Aero lumbar fusion system
  • Caranx Medical surgical robot TaviPilot AI software wins FDA clearance
  • InspireMD launches carotid stent in U.S. after FDA approval
  • Neuros Medical raises $56M Series D to support nerve stim tech
  • CorWave reports first-in-human LVAD implant

About Danielle Kirsh

Danielle Kirsh is an award-winning journalist and senior editor for Medical Design & Outsourcing, MassDevice, and Medical Tubing + Extrusion, and the founder of Women in Medtech and lead editor for Big 100. She received her bachelor's degree in broadcast journalism and mass communication from Norfolk State University and is pursuing her master's in global strategic communications at the University of Florida. You can connect with her on Twitter and LinkedIn, or email her at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy